Standard BioTools Inc. Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased
Standard BioTools Inc. (LAB) had Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased of 14.60 million shares as of 2023-06-30, per its 10-Q filed 2023-08-08.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased · last filed 2023-08-08
- 2023-06-30: Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased 14.60M shares.
- 2023-03-31: Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased 17.00M shares.
- 2022-12-31: Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased 19.40M shares.
| Period end | Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased |
|---|---|
| 2023-06-30 | 14.60M shares 10-Q · filed 2023-08-08 |
| 2023-03-31 | 17.00M shares 10-Q · filed 2023-05-09 |
| 2022-12-31 | 19.40M shares 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |